TY - JOUR T1 - A pooled analysis of the duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine JF - medRxiv DO - 10.1101/19002741 SP - 19002741 AU - MT Bretscher AU - P Dahal AU - J Griffin AU - K Stepniewska AU - Q Bassat AU - E Baudin AU - U D’Alessandro AU - AA Djimde AU - G Dorsey AU - E Espié AU - B Fofana AU - R González AU - E Juma AU - C Karema AU - E Lasry AU - B Lell AU - N Lima AU - C Menéndez AU - G Mombo-Ngoma AU - C Moreira AU - F Nikiema AU - JB Ouédraogo AU - SG Staedke AU - H Tinto AU - I Valea AU - A Yeka AU - AC Ghani AU - PJ Guerin AU - LC Okell Y1 - 2019/01/01 UR - http://medrxiv.org/content/early/2019/07/20/19002741.abstract N2 - Artemether-lumefantrine (AL) and artesunate-amodiaquine (AS-AQ) are the most commonly-used treatments against Plasmodium falciparum malaria in Africa. The lumefantrine and amodiaquine partner drugs may provide differing durations of post-treatment prophylaxis, an important additional benefit to patients. Analyzing 4214 individuals from clinical trials in 12 sites, we estimated a mean duration of post-treatment protection of 13.0 days (95% CI 10.7-15.7) for AL and 15.2 days (95% CI 12.8-18.4) for AS-AQ after allowing for transmission intensity. However, the duration varied substantially between sites: where wild type pfmdr1 86 and pfcrt 76 parasite genotypes predominated, AS-AQ provided ∼2-fold longer protection than AL. Conversely, AL provided up to 1.5-fold longer protection than AS-AQ where mutants were common. We estimate that choosing AL or AS-AQ as first-line treatment according to local drug sensitivity could alter population-level clinical incidence of malaria by up to 14% in under-five year olds where malaria transmission is high.Competing Interest StatementLCO declares prior grant funding from the World Health Organization and Medicines for Malaria Venture in addition to the funding already declared in the acknowledgements. The other authors declare no competing interests.Funding StatementThis work was supported by Medicines for Malaria Venture. LCO also acknowledges funding from a UK Royal Society Dorothy Hodgkin fellowship, the Bill & Melinda Gates Foundation, a joint fellowship from the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement, and joint Centre funding from the UK Medical Research Council and DFID (MR/R015600/1). ISGlobal is a member of the CERCA Programme, Generalitat de Catalunya (http://cerca.cat/en/suma/). CISM is supported by the Government of Mozambique and the Spanish Agency for International Development (AECID).Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.Not ApplicableAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.Not ApplicableAnalysis code in R and the transmission model executable file are fully available online at https://github.com/lucyokell/duration_protection_AL_ASAQ, as are the data underlying the figures: (Zenodo data repository DOI 10.5281/zenodo.3339215). The source code for the transmission model in C++ will be made available on Github prior to any full manuscript submission. The original individual level clinical trial data is available upon request from WWARN (https://www.wwarn.org/accessing-data). Requests must be approved by the data contributor and the WWARN Malaria Data Access Committee. https://github.com/lucyokell/duration_protection_AL_ASAQ https://doi.org/10.5281/zenodo.3339215 https://www.wwarn.org/accessing-data ER -